|
1
|
Dekker E, Tanis PJ, Vleugels J, Kasi PM
and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Goding Sauer A,
Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal
A: Colorectal cancer statistics, 2020. CA Cancer J Clin.
70:145–164. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dawson MJ and Trapani JA: IFI 16 gene
encodes a nuclear protein whose expression is induced by
interferons in human myeloid leukaemia cell lines. J Cell Biochem.
57:39–51. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wei W, Clarke CJ, Somers GR, Cresswell KS,
Loveland KA, Trapani JA and Johnstone RW: Expression of IFI16 in
epithelial cells and lymphoid tissues. Histochem Cell Biol.
119:45–54. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stehlik C: The PYRIN domain in signal
transduction. Curr Protein Pept Sci. 8:293–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Choubey D and Panchanathan R: IFI16, an
amplifier of DNA-damage response: Role in cellular senescence and
aging-associated inflammatory diseases. Ageing Res Rev. 28:27–36.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin H and Cao X: Nuclear innate sensors
for nucleic acids in immunity and inflammation. Immunol Rev.
297:162–173. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pancanathan R, Liu H, Leung YK, Ho SM and
Choubey D: Bisphenol A (BPA) stimulates the interferon signaling
and activates the inflammasome activity in meloid cells. Mol Cell
Endocrinol. 415:45–55. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cui J, Chen Y, Wang HY and Wang RF:
Mechanisms and pathways of innate immune activation and regulation
in health and cancer. Hum Vaccin Immunother. 10:3270–3285. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ouchi M and Ouchi T: Role of IFI16 in DNA
damage and checkpoint. Front Biosci. 13:236–239. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Duan X, Ponomareva L, Veeranki S and
Choubey D: IFI16 induction by glucose restriction in human
fibroblasts contributes to autophagy through activation of the
ATM/AMPK/p53 pathway. PLoS One. 6:e195322011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Howell RD, Alfonso DT, Yu J, Kong
L, Wittig JC and Liu CJ: IFI16 inhibits tumorigenicity and cell
proliferation of bone and cartilage tumor cells. Front Biosci.
12:4855–4863. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Raffaella R, Gioia D, De Andrea M,
Cappello P, Giovarelli M, Marconi P, Manservigi R, Gariglio M and
Landolfo S: The interferon-inducible IFI16 gene inhibits tube
morphogenesis and proliferation of primary, but not HPV16 E6/E7
immortalized human endothelial cells. Exp Cell Res. 293:331–345.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fujiuchi N, Aglipay JA, Ohtsuka T, Maehara
N, Sahin F, Su GH, Lee SW and Ouchi T: Requirement of IFI16 for the
maximal activation of p53 induced by ionizing radiation. J Biol
Chem. 279:20339–20344. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alimirah F, Chen J, Davis FJ and Choubey
D: IFI16 in human prostate cancer. Mol Cancer Res. 5:251–259. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cai H, Yan L, Liu N, Xu M and Cai H: IFI16
promotes cervical cancer progression by upregulating PD-L1 in
immunomicroenvironment through STING-TBK1-NF-κB pathway. Biomed
Pharmacother. 123:1097902020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim MK, Mason JM, Li CM, Berkofsky-Fessler
W, Jiang L, Choubey D, Grundy PE, Tycko B and Licht JD: A
pathologic link between Wilms tumor suppressor gene, WT1, and
IFI16. Neoplasia. 10:69–78. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu F, Hao X, Zhao H, Ge C, Yao M, Yang S
and Li J: Delta-like 1 contributes to cell growth by increasing the
interferon-inducible protein 16 expression in hepatocellular
carcinoma. Liver Int. 30:703–714. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shi XL, Yang J, Mao N, Wu JH, Ren LF, Yang
Y, Yin XL, Wei L, Li MY and Wang BN: Nutlin-3-induced
redistribution of chromatin-bound IFI16 in human hepatocellular
carcinoma cells in vitro is associated with p53 activation. Acta
Pharmacol Sin. 36:252–258. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shi X, Liu J, Liu Q and Li M: IFI16
mis-localization can be a contributing factor to hepatocellular
carcinoma progression. Med Hypotheses. 82:398–400. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang H, Guo Q, Zhang C, Zhu J, Yang H, Zou
YL, Yan Y, Hong D, Shou T and Yan XM: Identification of an
intermediate signature that marks the initial phases of the
colorectal adenoma-carcinoma transition. Int J Mol Med. 26:631–641.
2010.PubMed/NCBI
|
|
22
|
Yang CA, Huang HY, Chang YS, Lin CL, Lai
IL and Chang JG: DNA-Sensing and nuclease gene expressions as
markers for colorectal cancer progression. Oncology. 92:115–124.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Turkington CJR, Varadan AC, Grenier SF and
Grasis JA: The viral Janus: Viruses as aetiological agents and
treatment options in colorectal cancer. Front Cell Infect
Microbiol. 10:6015732020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Torlakovic EE, Nielsen S, Francis G,
Garratt J, Gilks B, Goldsmith JD, Hornick JL, Hyjek E, Ibrahim M,
Miller K, et al: Standardization of positive controls in diagnostic
immunohistochemistry: Recommendations from the international Ad Hoc
Expert Committee. Appl Immunohistochem Mol Morphol. 23:1–18. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Skaland I, Nordhus M, Gudlaugsson E, Klos
J, Kjellevold KH, Janssen EA and Baak JP: Evaluation of 5 different
labeled polymer immunohistochemical detection systems. Appl
Immunohistochem Mol Morphol. 18:90–96. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Muto T, Bussey HJ and Morson BC: The
evolution of cancer of the colon and rectum. Cancer. 36:2251–2270.
1975. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Greene FL: Current TNM staging of
colorectal cancer. Lancet Oncol. 8:572–573. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li LT, Jiang G, Chen Q and Zheng JN: Ki67
is a promising molecular target in the diagnosis of cancer
(review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Piccaluga PP, Agostinelli C, Righi S,
Ciccone M, Re MC, Musumeci G, Diani E, Signoretto C, Bon L, Piccin
O, et al: IFI16 reduced expression is correlated with unfavorable
outcome in chronic lymphocytic leukemia. APMIS. 125:511–522. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Man SM, Karki R and Kanneganti T:
DNA-sensing inflammasomes: Regulation of bacterial host defense and
the gut microbiota. Pathog Dis. 74:ftw282016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Veeranki S and Choubey D: Systemic lupus
erythematosus and increased risk to develop B cell malignancies:
Role of the p200-family proteins. Immunol Lett. 133:1–5. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Salama R, Sadaie M, Hoare M and Narita M:
Cellular senescence and its effector programs. Genes Dev.
28:99–144. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sharpless NE and Sherr CJ: Forging a
signature of in vivo senescence. Nat Rev Cancer. 15:397–408. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo Y, Ayers JL, Carter KT, Wang T, Maden
SK, Edmond D, Newcomb PP, Li C, Ulrich C, Yu M and Grady WM:
Senescence-associated tissue microenvironment promotes colon cancer
formation through the secretory factor GDF15. Aging Cell.
18:e130132019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Demaria M, Q'Leary MN, Chang J, Shao L,
Liu S, Alimirah F, Koening K, Le C, Mitin N, Deal AM, et al:
Cellular senescence promotes adverse effects of chemotherapy and
cancer relapse. Dancer Dissov. 7:165–176. 2017.PubMed/NCBI
|
|
36
|
Lai E, Liscia N, Donisi C, Mariani S, Tolu
S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, et al:
Molecular-Biology-Driven treatment for metastatic colorectal
cancer. Cancers (Basel). 12:12142020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lizardo DY, Kuang C, Hao S, Yu J, Huang Y
and Zhang L: Immunotherapy efficacy on mismatch repair-deficient
colorectal cancer: From bench to bedside. Biochim Biophys Acta Rev
Cancer. 1874:1884472020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Evrard C, Tachon G, Randrian V,
Karayan-Tapon L and Tougeron D: Microsatellite instability:
Diagnosis, heterogeneity, discordance, and clinical impact in
colorectal cancer. Cancers (Basel). 11:15672019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Keshet Y and Seger R: The MAP kinase
signaling cascades: A system of hundreds of components regulates a
diverse array of physiological functions. Mothods Mol Biol.
661:3–38. 2010.PubMed/NCBI
|
|
41
|
Sun Y, Liu WZ, Liu T, Feng X, Yang N and
Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation,
differentiation, migration, senescence and apoptosis. J Recept
Signal Transduct Res. 35:600–604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ye Q, Cai W, Zheng Y, Evers BM and She QB:
ERK and AKT signaling cooperate to translationally regulate
survivin expression for metastatic progression of colorectal
cancer. Oncogene. 33:1828–1839. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ding B and Lengyel P: p204 protein is a
novel modulator of ras activity. J Biol Chem. 283:5831–5848. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Luan Y, Lengyel P and Liu CJ: p204, a p200
family protein, as a multifunctional regulator of cell
proliferation and differentiation. Cytokine Growth Factor Rev.
19:357–369. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim EJ, Park JI and Nelkin BD: IFI16 is an
essential mediator of growth inhibition, but not differentiation,
induced by the leukemia inhibitory factor/JAK/STAT pathway in
medullary thyroid carcinoma cells. J Biol Chem. 280:4913–4920.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lengyel P and Liu CJ: The p200 family
protein p204 as a modulator of cell proliferation and
differentiation: A brief survey. Cell Mol Life Sci. 67:335–340.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kolc W: Coordinating ERK/MAPK signalling
through scaffolds and inhibitors. Nat Rev Mol Cell Biol. 6:827–837.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Brunet A, Roux D, Lenormand P, Dowd S,
Keyse S and Pouysségur J: Nuclear translocation of p42/p44
mitogen-activated protein kinase is required for growth
factor-induced gene expression and cell cycle entry. EMBO J.
18:664–674. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Su N, Peng L, Xia B, Zhao Y, Xu A, Wang J,
Wang X and Jiang B: Lyn is involved in CD24-induced ERK1/2
activation in colorectal cancer. Mol Cancer. 11:432012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Whitehurst AW, Robinson FL, Moore MS and
Cobb M: The death effector domain protein PEA-15 prevents nuclear
entry of ERK2 by inhibiting required interactions. J Biol Chem.
279:12840–12847. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Torii S, Kusakabe M, Yamamoto T, Maekawa M
and Nishida E: Sef is a spatial regulator forr Ras/MAP kinase
signaling. Dev Cell. 7:33–44. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gil-Jaramillo N, Rocha AP, Raiol T, Motta
FN, Favali C, Brigido MM, Bastos IMD and Santana JM: Trypanosoma
cruzi The First Contact of human Dendritic cells with reveals
response to virus as an unexplored central pathway. Front Immunol.
12:6380202021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lu N and Malemud CJ: Extracellular
signal-regulated Kinase: A regulator of cell growth, inflammation,
chondrocyte and bone cell receptor-mediated gene expression. Int J
Mol Sci. 20:37922019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kis-Toth K, Szanto A, Thai TH and Tsokos
GC: Cytosolic DNA-activated human dendritic cells are potent
activators of the adaptive immune response. J Immunol.
187:1222–1234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Qi Z, Yan F, Chen D, Xing W, Li Q, Zeng W,
Bi B and Xie J: Identification of prognostic biomarkers and
correlations with immune infiltrates among Cgas-STING in
hepatocellular carcinoma. Biosci Rep. 40:BSR202026032020.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-pages C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density, and location of immune
cells within human colorectal tumors predict clinical outcome.
Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mlecnik B, Tosolini M, Kirilovsky A,
Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman
WH, Pagès F and Galon J: Histopathologic-based prognostic factors
of colorectal cancers are associated with the state of the local
immune reaction. J Clin Oncol. 29:610–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Payandeh Z, Khalili S, Somi M,
Mard-Soltani M, Baghbanzadeh A, Hajiasgharzadeh K, Samadi N and
Baradaran B: PD-1/PD-L1-dependent immune response in colorectal
cancer. J Cell Physiol. 235:5461–5475. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Peng QH, Wang CH, Chen HM, Zhang RX, Pan
ZZ, Lu ZH, Wang GY, Yue X, Huang W and Liu RY: CMTM6 and PD-L1
coexpression is associated with an active immune microenvironment
and a favorable prognosis in colorectal cancer. J Immunother
Cancer. 9:e0016382021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Akiyoshi T, Gotoh O, Tanaka N, Kiyotani K,
Yamamoto N, Ueno M, Fukunaga Y and Mori S: T-cell complexity and
density are associated with sensitivity to neoadjuvant
chemoradiotherapy in patients with rectal cancer. Cancer Immunol
Immunother. 70:509–518. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kikuchi T, Mimura K, Okayama H, Nakayama
Y, Saito K, Yamada L, Endo E, Sakamoto W, Fujita S, Endo H, et al:
A subset of patients with MSS/MSI-low-colorectal cancer showed
increased CD8(+) TILs together with up-regulated IFN-γ. Oncol Lett.
18:5977–5985. 2019.PubMed/NCBI
|
